Donor Substitution Engineering of Hemicyanine Nanoparticles to Reprogram the Tumor Microenvironment and Enhance Fn14‐Targeted BiTE for Glioblastoma Photoimmunotherapy
Gaowei Li,Shichao Jiang,Zongliang Zhang,Xiaoyin Liu,Kai Wu,Peng Liu,Mei Yang,Ting Zhou,Jiamei Xiao,Nini Xin,Xiaoyang Wu,Zhihong Chen,Jie Ding,Chengheng Wu,Dan Wei,Jing Sun,Aiping Tong,Hongsong Fan,Liangxue Zhou
DOI: https://doi.org/10.1002/adfm.202413847
IF: 19
2024-11-07
Advanced Functional Materials
Abstract:This study introduces an innovative strategy using hemicyanine‐based nanoparticles (PLH1100) for glioblastoma therapy. By improving T cell infiltration and activation in the tumor microenvironment, PLH1100 enhances photothermal tumor ablation, regulates lactic acid metabolism, and activates immune responses. It synergistically boosts the efficacy of Fn14‐targeted BiTE therapy, presenting a promising new approach for effective glioblastoma treatment. Glioblastoma (GBM) is a highly malignant intracranial tumor with limited treatment options. Bispecific T‐cell engagers (BiTEs) are being explored for GBM treatment, but their success is hindered by inadequate T cell infiltration and activation due to the acidic and immunosuppressive microenvironment. Photothermal immunotherapy lyses tumors and activates immune responses, complementing BiTEs. This study innovatively employs a donor engineering strategy to develop hemicyanine dyes (Hcys) that emit from near‐infrared (NIR) I to NIR II. The Hcy with excellent properties is encapsulated in an amphiphilic micelle, forming a nano assembly with lactate oxidase (PLH1100). PLH1100 exhibits spectral absorption at 980 nm, a photothermal conversion efficiency of 58.7%, and capability for NIR‐II tumor imaging. Besides photothermal tumor ablation, PLH1100 regulates lactic acid metabolism and activates immunogenic cell death, improving the tumor microenvironment and promoting T cell infiltration and activation. Further studies demonstrate PLH1100 effectively kills human and murine GBM cells, inhibits orthotopic U87 tumor growth in BALB/c‐nu mice, and enhances the efficacy of Fn14‐targeted BiTE in orthotopic GL261 tumors in C57BL/6 mice, achieving a synergistic "1+1>2" therapeutic effect. Collectively, this work opens a new pathway for using Hcy‐based molecules combined with BiTE drugs for GBM therapy, with significant clinical potential.
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology